Aurora(ACB) - 2026 Q1 - Earnings Call Presentation

Financial Performance & Growth - Global medical cannabis net revenue reached $64.8 million in Q1, a 37% increase compared to the prior year period[17] - Aurora achieved positive free cash flow of $9.2 million in Q1 FY26, representing 42% year-over-year growth[111] - The company achieved positive adjusted EBITDA of $10.8 million in Q1 FY26, a 209% increase year-over-year[111] - Bevo contributed record revenues of approximately $23.9 million in Q1, up 4% compared to the prior year period[99] Market Leadership & Expansion - International medical revenue increased 85% in Q1 FY 2026 compared to the prior year period[9] - Aurora is the 1 Canadian Medical share by revenue, with net revenue increasing by 2% compared to the prior year period[9] - Aurora Europe was the 2 supplier of medical cannabis to each core market of Germany and Poland in Q1 FY26[35] - MedReleaf Australia, an Aurora subsidiary, holds approximately 16% market share by revenue and pharmacy dispensed volumes in Australia[57] Product Innovation & Strategy - Innovations in genetics result in all-in per unit costs that are at least 30% better than legacy cultivars[12] - Farm Gas became the 1 selling cultivar in Poland shortly after its launch, with THC levels around 27%[22, 36]